BYU

Abstract by Phil Smit

Personal Infomation


Presenter's Name

Phil Smit

Degree Level

Undergraduate

Abstract Infomation


Department

Chemistry and Biochemistry

Faculty Advisor

Richard Watt

Title

Furin Inhibition: A Potential Treatment for Liver Fibrosis

Abstract

Transforming Growth Factor β (TGF-β), an inflammatory cytokine, has been shown to directly upregulate fibrosis in the extra cellular matrix (ECM), leading to elevated ECM remodeling, or fibrosis, by activating matrix metalloproteases (MMPs). Other groups showed that Furin processes inactive proTGF-β, transforming it into TGF-β. Nelfinavir and Darunavir are FDA approved protease inhibitors used to treat HIV, and our lab has shown they can be used to inhibit Furin to treat anemia. No data exists to show that these drugs inhibit Furin to treat fibrosis. Our goals are to demonstrate that Furin inhibition can block TGF-β and MMP activation. This could be a potential treatment for lung and liver fibrosis. Data will be presented to show inhibition of pro-MMP-14, pro-TGF-B and Pro-hepcidin activation by Nelfinavir.